O
TPTX

OrbiMed’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

OrbiMed’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,012,250
Closed -$151K – 154
2022
Q2 		$151K Sell
2,012,250
-6,700
-0.3% -$298K 2.74% 6
2022
Q1 		$54.2M Sell
2,018,950
-87,500
-4% -$2.94M 0.88% 36
2021
Q4 		$100M Sell
2,106,450
-254,877
-11% -$11.4M 1.29% 27
2021
Q3 		$157M Hold
2,361,327
– – 1.72% 15
2021
Q2 		$184M Hold
2,361,327
– – 1.86% 14
2021
Q1 		$223M Sell
2,361,327
-384,000
-14% -$45.7M 2.09% 13
2020
Q4 		$335M Hold
2,745,327
– – 2.93% 6
2020
Q3 		$240M Hold
2,745,327
– – 3.01% 5
2020
Q2 		$177M Hold
2,745,327
– – 2.5% 11
2020
Q1 		$123M Hold
2,745,327
– – 2.06% 14
2019
Q4 		$171M Hold
2,745,327
– – 2.44% 12
2019
Q3 		$103M Buy
2,745,327
+177,777
+7% +$7.74M 1.96% 13
2019
Q2 		$104M Buy
+2,567,550
New +$91.6M 1.62% 16

OrbiMed's TPTX Position: Q3 2022 in Review

OrbiMed sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 2,012,250 shares — an estimated $151K sold.

OrbiMed first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $335M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • OrbiMed reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • OrbiMed sold 2,012,250 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $151K.
  • OrbiMed first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
  • OrbiMed's Turning Point Therapeutics, Inc. Common Stock position peaked at $335M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.